Published in BJU Int on August 26, 2011
Mechanisms of cryoablation: clinical consequences on malignant tumors. Cryobiology (2013) 0.89
Extracts from glioma tissues following cryoablation have proapoptosis, antiproliferation, and anti-invasion effects on glioma cells. Biomed Res Int (2014) 0.75
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol (2008) 2.85
Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. Oncogene (2001) 2.17
Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res (1990) 2.00
Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer (1993) 1.94
Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology (2000) 1.90
Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res (1998) 1.46
Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology (2002) 1.41
Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res (2000) 1.30
Image-guided prostate cryosurgery: state of the art. Cancer Control (2002) 1.22
BCL-2 in prostate cancer: a minireview. Apoptosis (2003) 1.22
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer (2002) 1.22
Chemo-cryo combination therapy: an adjunctive model for the treatment of prostate cancer. Cryobiology (2001) 1.09
Cryosurgery--a putative approach to molecular-based optimization. Cryobiology (2004) 1.08
Cryosurgery as a treatment for prostate carcinoma: results and complications. Cancer (1997) 1.07
Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology (2001) 1.07
Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res (2006) 1.07
Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol (2006) 1.03
Clinical trials in metastatic prostate cancer--has there been real progress in the past decade? Eur J Cancer (2005) 1.01
Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology (2008) 0.99
Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells. Mol Cancer Ther (2005) 0.95
Progress toward optimization of cryosurgery. Technol Cancer Res Treat (2004) 0.92
Cryosurgery for tumors - a clinical overview. Technol Cancer Res Treat (2004) 0.92
Addition of anticancer agents enhances freezing-induced prostate cancer cell death: implications of mitochondrial involvement. Cryobiology (2004) 0.92
Update on erectile dysfunction in prostate cancer patients. Curr Opin Urol (2006) 0.91
Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer (2003) 0.90
Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J Nutr (2003) 0.87
Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy. Oncology (2003) 0.86
A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology (2004) 0.86
Cryoablative response of prostate cancer cells is influenced by androgen receptor expression. BJU Int (2008) 0.85
Ultrasound guided combined cryoablation and microencapsulated 5-Fluorouracil inhibits growth of human prostate tumors in xenogenic mouse model assessed by luminescence imaging. Technol Cancer Res Treat (2004) 0.84
Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy. Prostate Cancer Prostatic Dis (2005) 0.82
Introduction. Recent scientific and technological advances have challenged the traditional treatment options for patients with localized prostate cancer. Urology (2002) 0.81
Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. Oncology (2003) 0.81
Second generation taxanes: from the natural framework to the challenge of drug resistance. Curr Med Chem Anticancer Agents (2003) 0.81
Development of a tissue engineered human prostate tumor equivalent for use in the evaluation of cryoablative techniques. Technol Cancer Res Treat (2007) 0.80
Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer. Prostate Cancer Prostatic Dis (2007) 0.80
Role of vitamin D(3) as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study. Urology (2010) 0.79
Minimally invasive approaches to localized prostate carcinoma. Hematol Oncol Clin North Am (2006) 0.79
Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. Acta Oncol (2003) 0.78
BCL2 antisense reduces prostate cancer cell survival following irradiation. Cancer Biother Radiopharm (2002) 0.78
Non-genomic effects of the androgen receptor and vitamin D agonist are involved in suppressing invasive phenotype of prostate cancer cells. Steroids (2005) 0.78
Current status of salvage cryoablation for prostate cancer following radiation failure. Technol Cancer Res Treat (2005) 0.78
Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. World J Urol (2005) 0.76
Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol (2008) 4.75
Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol (2008) 2.85
Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol (2007) 2.42
The state of prostate MRI in 2013. Oncology (Williston Park) (2013) 2.33
Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. Prostate (2008) 2.16
Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology (2009) 2.09
Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol (2010) 2.05
Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. J Urol (2009) 2.03
Promoter hypermethylation profile of kidney cancer. Clin Cancer Res (2004) 2.02
Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev (2008) 1.99
Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol (2012) 1.95
Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study. BJU Int (2013) 1.89
Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol (2009) 1.85
Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int (2007) 1.71
Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer (2008) 1.71
Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer (2010) 1.59
Factors predicting prostatic biopsy Gleason sum under grading. J Urol (2009) 1.59
Complications of laparoscopic and percutaneous renal cryoablation in a single tertiary referral center. Eur Urol (2010) 1.53
Focal therapy for prostate cancer is a reasonable treatment option in properly selected patients. Urology (2009) 1.49
Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials (2008) 1.48
Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol (2002) 1.48
Current status of minimally invasive ablative techniques in the treatment of small renal tumours. Eur Urol (2006) 1.47
Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol (2010) 1.45
Predicting occult multifocality of renal cell carcinoma. Eur Urol (2010) 1.45
Predictors of biochemical failure in patients undergoing prostate whole-gland salvage cryotherapy: a novel risk stratification model. BJU Int (2013) 1.44
The molecular basis of cryosurgery. BJU Int (2005) 1.40
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int (2011) 1.37
Treatment of localised renal cell carcinoma. Eur Urol (2011) 1.29
Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer (2007) 1.27
Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology (2009) 1.18
Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology (2008) 1.15
Complications after percutaneous radiofrequency ablation of renal tumors. Urology (2005) 1.10
Cryosurgery--a putative approach to molecular-based optimization. Cryobiology (2004) 1.08
Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Hum Gene Ther (2003) 1.08
Editorial comment to Manually controlled targeted prostate biopsy with real-time fusion imaging of multiparametric magnetic resonance imaging and transrectal ultrasound: an early experience. Int J Urol (2014) 1.07
Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int (2008) 1.07
Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol (2009) 1.07
Acoustic radiation force impulse imaging of human prostates: initial in vivo demonstration. Ultrasound Med Biol (2011) 1.06
Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int (2009) 1.06
Acoustic radiation force impulse imaging of human prostates ex vivo. Ultrasound Med Biol (2010) 1.04
Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer (2011) 1.04
Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU Int (2010) 1.04
Characterizing stiffness of human prostates using acoustic radiation force. Ultrason Imaging (2010) 1.04
Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol (2006) 1.03
Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer (2009) 1.02
Cryoablation of renal cancer: variables involved in freezing-induced cell death. Technol Cancer Res Treat (2007) 1.02
Cryosurgery for tumors. J Am Coll Surg (2007) 1.02
Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int (2009) 1.01
Cryosurgery - a review of recent advances and current issues. Cryo Letters (2002) 1.00
Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer (2010) 0.98
Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology (2007) 0.98
Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol (2011) 0.98
Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology (2009) 0.97
Focal therapy for prostate cancer: possibilities and limitations. Eur Urol (2010) 0.97
Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag (2008) 0.97
Prostate cancer: the new landscape. Curr Opin Urol (2009) 0.97
Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. J Sex Med (2011) 0.96
Supplement use among men with prostate cancer. Urology (2005) 0.95
Effect of freeze time during renal cryoablation: a swine model. J Endourol (2006) 0.95
Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology (2004) 0.94
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. J Urol (2011) 0.94
Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int (2014) 0.93
Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila) (2011) 0.92
Addition of anticancer agents enhances freezing-induced prostate cancer cell death: implications of mitochondrial involvement. Cryobiology (2004) 0.92
Cryosurgery for tumors - a clinical overview. Technol Cancer Res Treat (2004) 0.92
Clinical predictors of renal mass pathological features. BJU Int (2010) 0.92
Time course of esophageal lesions after catheter ablation with cryothermal and radiofrequency ablation: implication for atrio-esophageal fistula formation after catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol (2007) 0.92
Urinary bladder cancer: role of MR imaging. Radiographics (2012) 0.92
A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. J Clin Anesth (2009) 0.91
Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology (2007) 0.91
Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model. Cancer Res (2003) 0.91
Management of small renal tumors with radiofrequency ablation. Urology (2003) 0.91
The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy. Urology (2012) 0.91
Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. BJU Int (2010) 0.90
Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? Urology (2009) 0.90
Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. Int J Radiat Oncol Biol Phys (2011) 0.90
Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer (2002) 0.90
Autoimmune testicular vasculitis. Urology (2003) 0.88
The rise of ablative technologies for treating the small renal mass. Eur Urol (2007) 0.88